» Authors » Sam Chen

Sam Chen

Explore the profile of Sam Chen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 1898
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
21.
Chen S, Tam Y, Lin P, Sung M, Tam Y, Cullis P
J Control Release . 2016 May; 235:236-244. PMID: 27238441
Lipid nanoparticles (LNP) can provide a clinically effective method for delivering small interfering RNA (siRNA) to silence pathological genes in hepatocytes. The gene silencing potency of these LNP-siRNA systems has...
22.
Leung A, Tam Y, Chen S, Hafez I, Cullis P
J Phys Chem B . 2015 Jun; 119(28):8698-706. PMID: 26087393
Previous work has shown that lipid nanoparticles (LNP) composed of an ionizable cationic lipid, a poly(ethylene glycol) (PEG) lipid, distearoylphosphatidylcholine (DSPC), cholesterol, and small interfering RNA (siRNA) can be efficiently...
23.
Chen S, Tam Y, Lin P, Leung A, Tam Y, Cullis P
J Control Release . 2014 Oct; 196:106-12. PMID: 25285610
Recently developed lipid nanoparticle (LNP) formulations of siRNA have proven to be effective agents for hepatocyte gene silencing following intravenous administration with at least three LNP-siRNA formulations in clinical trials....
24.
Walsh C, Ou K, Belliveau N, Leaver T, Wild A, Huft J, et al.
Methods Mol Biol . 2014 Feb; 1141:109-20. PMID: 24567134
A simple, efficient, and scalable manufacturing technique is required for developing siRNA-lipid nanoparticles (siRNA-LNP) for therapeutic applications. In this chapter we describe a novel microfluidic-based manufacturing process for the rapid...
25.
Neumann U, Chen S, Tam Y, Baker R, Covey S, Cullis P, et al.
Endocrinology . 2014 Jan; 155(3):716-25. PMID: 24424049
The ability of leptin to improve metabolic abnormalities in models of leptin deficiency, lipodystrophy, and even type 1 diabetes is of significant interest. However, the mechanism by which leptin mediates...
26.
Mui B, Tam Y, Jayaraman M, Ansell S, Du X, Tam Y, et al.
Mol Ther Nucleic Acids . 2013 Dec; 2:e139. PMID: 24345865
Lipid nanoparticles (LNPs) encapsulating short interfering RNAs that target hepatic genes are advancing through clinical trials, and early results indicate the excellent gene silencing observed in rodents and nonhuman primates...
27.
Tam Y, Chen S, Cullis P
Pharmaceutics . 2013 Dec; 5(3):498-507. PMID: 24300520
Technological advances in both siRNA (small interfering RNA) and whole genome sequencing have demonstrated great potential in translating genetic information into siRNA-based drugs to halt the synthesis of most disease-causing...
28.
Belliveau N, Huft J, Lin P, Chen S, Leung A, Leaver T, et al.
Mol Ther Nucleic Acids . 2013 Jan; 1:e37. PMID: 23344179
Lipid nanoparticles (LNP) are the leading systems for in vivo delivery of small interfering RNA (siRNA) for therapeutic applications. Formulation of LNP siRNA systems requires rapid mixing of solutions containing...
29.
Tam Y, Chen S, Zaifman J, Tam Y, Lin P, Ansell S, et al.
Nanomedicine . 2012 Dec; 9(5):665-74. PMID: 23219877
From The Clinical Editor: In this study, the authors identified small molecules that enhance cellular uptake of lipid nanoparticle siRNA systems, then used them as LNP-associated ligands to improve gene...
30.
Lin P, Tam Y, Hafez I, Sandhu A, Chen S, Ciufolini M, et al.
Nanomedicine . 2012 Jun; 9(2):233-46. PMID: 22698807
From The Clinical Editor: This study reports on the in vivo gene silencing potency of lipid nanoparticle-siRNA systems containing ionizable cationic lipids. It is concluded that the superior potency of...